Silence Therapeutics PLC Results of Placing (9592D)

TIDMSLN

RNS Number : 9592D

Silence Therapeutics PLC

12 October 2018

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

For immediate release

Patisserie Holdings PLC

12 October 2018

Results of Placing to raise approximately GBP15.7m

Further to the earlier announcement in relation to the proposed placing of ordinary shares, the Company announces that 31,451,100 ordinary shares (the "Placing Shares") have been placed with institutional investors and were placed at a price of 50p per share via an accelerated bookbuild (the "Placing"). Canaccord Genuity ("Canaccord Genuity") acted as nominated adviser, sole bookrunner and broker in connection with the Placing. The Placing raised approximately GBP15.7 million before expenses.

Application will be made for the admission of 31,451,100 ordinary shares to trading on AIM. It is expected that admission of (a) the Firm Placing Shares comprising 10,000,000 ordinary shares will become effective at 8.00 a.m. on 18 October 2018 and that dealings in the Firm Placing Shares will commence at that time and (b) the Conditional Placing Shares comprising 21,451,100 ordinary shares will become effective at 8.00 a.m. on the Business Day following the General Meeting of the Company (expected to on or around 1 November 2018) and that dealings in the Firm Placing Shares will commence at that time and the Placing Shares shall rank pari passu with the existing issued ordinary shares of the Company.

Following completion of the Placing the Company will have 135,322,452 Ordinary Shares in issue.

Enquiries

   Patisserie Holdings PLC                         +44 (0)121 777 7000

Luke Johnson, Executive Chairman

Paul May, Chief Executive Officer

Nomad and Broker

   Canaccord Genuity Limited                     +44 (0)20 7523 8000

Chris Connors

Henry Fitzgerald-O'Connor

Financial Public Relations

   Maitland                                                +44 (0) 20 7379 5151

Sam Cartwright

Jonathan Cook

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROIEAKEAFFFPFFF

(END) Dow Jones Newswires

October 12, 2018 12:12 ET (16:12 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024